AC Immune Raises CHF 21 Million in Private Financing Round

AC Immune, a Swiss biotech company developing innovative therapies against Alzheimer's disease, announced that it has successfully completed its round B financing raising CHF 21 million from private and strategic investors. The financing goal of CHF 21 millions was achieved with two-thirds of the invested capital contributed by new investors. AC immune is focused on new therapies for the treatment of Alzheimer's disease using vaccination or passive immunization with antibodies.

Yahoo News (http://biz.yahoo.com/cnw/050511/ac_immune_21_million.html?.v=1)